EGFR and metastatic neoplasm: Osimertinib, a third generation EGFR inhibitor, is currently approved as first-line treatment for CNS metastatic disease in non-small cell lung cancer with EGFR mutations secondary to its high CNS penetrance and preclinical and clinical activity (74, 78).